A Japanese Approach for CKD-MBD

Overview

Journal Kidney Int Suppl (2011)

Publisher Elsevier

Specialty Nephrology

Date 2014 Jul 15

PMID 25019029

Citations 7

Authors

Keitaro Yokoyama

Masatomo Taniguchi

Masafumi Fukagawa

Affiliations

Soon will be listed here.

Abstract

Disturbances in mineral and bone metabolism have a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). The term 'renal osteodystrophy' has recently been replaced by 'CKD-mineral and bone disorder (CKD-MBD)', which includes abnormalities in bone and mineral metabolism and vascular calcification. The Japanese Society for Dialysis Therapy clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients was originally published in Japanese in 2006, then in English in 2008. During the past 5 years, this first guideline has contributed to a considerably better understanding and control of secondary hyperparathyroidism in CKD patients by physicians, other medical professionals, and the patients themselves. However, since its publication several new therapeutic modalities have become available for Japanese dialysis patients, which added more evidence to this area. Thus, we revised the guideline to include several new policies, and the new guideline was published in Japanese in 2012. This article contains the new guideline text, and clinical significance of CKD-MBD in Japan.

Citing Articles

Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.

Yokoyama K, Hashimoto T, Okuda Y, Matsumoto Y, Ito K, Yamada R Clin Exp Nephrol. 2022; 26(7):688-699.

PMID: 35258721 PMC: 9203387. DOI: 10.1007/s10157-022-02204-1.

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.

Shigematsu T, Asada S, Endo Y, Kawata T, Fukagawa M, Akizawa T PLoS One. 2022; 17(2):e0262829.

PMID: 35176038 PMC: 8853539. DOI: 10.1371/journal.pone.0262829.

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.

Akizawa T, Sato Y, Ikejiri K, Kanda H, Fukagawa M Kidney Int Rep. 2021; 6(9):2371-2380.

PMID: 34514198 PMC: 8418975. DOI: 10.1016/j.ekir.2021.06.030.

A Survey of Drug Burden in Patients Undergoing Maintenance Hemodialysis in Japan.

Iwashita Y, Ohya M, Kunimoto S, Iwashita Y, Mima T, Negi S Intern Med. 2018; 57(20):2937-2944.

PMID: 29780106 PMC: 6232020. DOI: 10.2169/internalmedicine.0108-17.

Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Bover J, Urena P, Ruiz-Garcia C, DaSilva I, Lescano P, Del Carpio J Clin J Am Soc Nephrol. 2015; 11(1):161-74.

PMID: 26224878 PMC: 4702220. DOI: 10.2215/CJN.01760215.

References

Goodman W, Hladik G, Turner S, Blaisdell P, Goodkin D, Liu W . The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002; 13(4):1017-1024. DOI: 10.1681/ASN.V1341017. View

Block G, Levin N, Port F . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31(4):607-17. DOI: 10.1053/ajkd.1998.v31.pm9531176. View

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara M, Rodriguez M, Aljama P . Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005; 46(1):68-77. DOI: 10.1053/j.ajkd.2005.04.006. View

Yokoyama K . The calcium-phosphorus in guidelines for CKD-MBD. Kidney Int. 2008; 74(2):245. DOI: 10.1038/ki.2008.175. View

Ganesh S, Stack A, Levin N, Hulbert-Shearon T, Port F . Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12(10):2131-2138. DOI: 10.1681/ASN.V12102131. View

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama J . Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013; 17(3):247-88. DOI: 10.1111/1744-9987.12058. View

. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1-130. DOI: 10.1038/ki.2009.188. View

Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y . Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial. 2008; 12(1):49-54. DOI: 10.1111/j.1744-9987.2007.00540.x. View

10.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K . Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. DOI: 10.1038/sj.ki.5000414. View

11.

Young E, Albert J, Satayathum S, Goodkin D, Pisoni R, Akiba T . Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67(3):1179-87. DOI: 10.1111/j.1523-1755.2005.00185.x. View

12.

Takahashi N, Shoji T, Matsubara K, Hitomi H, Hashimoto M, Kiyomoto H . Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. J Am Soc Nephrol. 1999; 10(5):1090-4. DOI: 10.1681/ASN.V1051090. View

13.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

14.

Kakuta T, Tanaka R, Kanai G, Sawaya A, Hirukawa T, Sato A . Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?. Ther Apher Dial. 2009; 13 Suppl 1:S20-7. DOI: 10.1111/j.1744-9987.2009.00772.x. View

15.

Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M . Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2007; 23(1):328-35. DOI: 10.1093/ndt/gfm534. View

16.

Llach F, Velasquez Forero F . Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis. 2001; 38(5 Suppl 5):S20-33. DOI: 10.1053/ajkd.2001.28113. View

17.

Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernandez-Martin J, Rodriguez-Puyol D . Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2010; 26(6):1938-47. DOI: 10.1093/ndt/gfq304. View

18.

. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2009; 12(6):514-25. DOI: 10.1111/j.1744-9987.2008.00648.x. View

19.

Komaba H, Fukagawa M . Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial. 2008; 12 Suppl 1:S44-9. DOI: 10.1111/j.1744-9987.2008.00631.x. View

20.

Yokoyama K, Katoh N, Kubo H, Murai S, Imamura N, Shoji R . Clinical significance of the K/DOQI bone guidelines in Japan. Am J Kidney Dis. 2004; 44(2):383-4. DOI: 10.1053/j.ajkd.2004.05.038. View